Editorial ArticleLife Sciences
Ultrasensitive immunoassay technology drives blood-based biomarkers for Alzheimer's disease
Leveraging Quanterix’s Simoa platform, researchers lay the groundwork for pre-symptomatic Alzheimers diagnosis, guided treatment, and accelerated clinical drug trials
